Cargando…

Comparative study on guidelines in determining HBV phases in Iranian patients

AIM: The aim of this study was to compare the different phases of chronic Hepatitis B virus (HBV) infection with different values for normal ALT. BACKGROUND: For many years, the upper limit of 40 IU was considered normal for ALT for both sexes, but in recent years this value is challenged and some g...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashtari, Sara, Sharifian, Afsaneh, Hatami, Behzad, Mohebbi, Seyed Reza, Nouri, Gholamreza, Bazdar, Monireh, Naderi, Nosratollah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shaheed Beheshti University of Medical Sciences 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011065/
https://www.ncbi.nlm.nih.gov/pubmed/32099615
_version_ 1783495998959517696
author Ashtari, Sara
Sharifian, Afsaneh
Hatami, Behzad
Mohebbi, Seyed Reza
Nouri, Gholamreza
Bazdar, Monireh
Naderi, Nosratollah
author_facet Ashtari, Sara
Sharifian, Afsaneh
Hatami, Behzad
Mohebbi, Seyed Reza
Nouri, Gholamreza
Bazdar, Monireh
Naderi, Nosratollah
author_sort Ashtari, Sara
collection PubMed
description AIM: The aim of this study was to compare the different phases of chronic Hepatitis B virus (HBV) infection with different values for normal ALT. BACKGROUND: For many years, the upper limit of 40 IU was considered normal for ALT for both sexes, but in recent years this value is challenged and some guidelines have lowered their limit. METHODS: In this cross-sectional study, 2000 HBsAg positive patients who were referred to Taleghani Hospital, Tehran, Iran, from 2011 through 2018 were classified in four groups according to American Association of the study of the liver disease (AASLD), European Association of the study of the liver (EASL) /Asian-Pacific Association of the study of the liver (APASL) and American Collage of Gastroenterology (ACG) guidelines. The frequency of each group based on 3 different guidelines was compared. RESULTS: In HBeAg positive patients (n=100), the percentage of immune tolerance phase was 43% according to AASLD cutoff for normal ALT (35 IU for men, 25 IU for women), while it was 68% and 28% with regard to EASL/APASL and ACG (30 IU for men, 19 IU for women) cutoffs respectively. In HBeAg negative patients (n=1900), 66.68% were inactive carriers according to AASLD, but the percentage changed to 82.89% and 52.42% considering EASL/APASL and ACG values, respectively. CONCLUSION: Using ACG and to a lesser extent AASLD cutoff for ALT, many patients shift from immune tolerance and inactive carrier state into the immune active phase. Thus, more patients are candidates for treatment or intensive workup to determine the extent of liver damage.
format Online
Article
Text
id pubmed-7011065
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Shaheed Beheshti University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-70110652020-02-25 Comparative study on guidelines in determining HBV phases in Iranian patients Ashtari, Sara Sharifian, Afsaneh Hatami, Behzad Mohebbi, Seyed Reza Nouri, Gholamreza Bazdar, Monireh Naderi, Nosratollah Gastroenterol Hepatol Bed Bench Original Article AIM: The aim of this study was to compare the different phases of chronic Hepatitis B virus (HBV) infection with different values for normal ALT. BACKGROUND: For many years, the upper limit of 40 IU was considered normal for ALT for both sexes, but in recent years this value is challenged and some guidelines have lowered their limit. METHODS: In this cross-sectional study, 2000 HBsAg positive patients who were referred to Taleghani Hospital, Tehran, Iran, from 2011 through 2018 were classified in four groups according to American Association of the study of the liver disease (AASLD), European Association of the study of the liver (EASL) /Asian-Pacific Association of the study of the liver (APASL) and American Collage of Gastroenterology (ACG) guidelines. The frequency of each group based on 3 different guidelines was compared. RESULTS: In HBeAg positive patients (n=100), the percentage of immune tolerance phase was 43% according to AASLD cutoff for normal ALT (35 IU for men, 25 IU for women), while it was 68% and 28% with regard to EASL/APASL and ACG (30 IU for men, 19 IU for women) cutoffs respectively. In HBeAg negative patients (n=1900), 66.68% were inactive carriers according to AASLD, but the percentage changed to 82.89% and 52.42% considering EASL/APASL and ACG values, respectively. CONCLUSION: Using ACG and to a lesser extent AASLD cutoff for ALT, many patients shift from immune tolerance and inactive carrier state into the immune active phase. Thus, more patients are candidates for treatment or intensive workup to determine the extent of liver damage. Shaheed Beheshti University of Medical Sciences 2019 /pmc/articles/PMC7011065/ /pubmed/32099615 Text en ©2019 RIGLD This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Ashtari, Sara
Sharifian, Afsaneh
Hatami, Behzad
Mohebbi, Seyed Reza
Nouri, Gholamreza
Bazdar, Monireh
Naderi, Nosratollah
Comparative study on guidelines in determining HBV phases in Iranian patients
title Comparative study on guidelines in determining HBV phases in Iranian patients
title_full Comparative study on guidelines in determining HBV phases in Iranian patients
title_fullStr Comparative study on guidelines in determining HBV phases in Iranian patients
title_full_unstemmed Comparative study on guidelines in determining HBV phases in Iranian patients
title_short Comparative study on guidelines in determining HBV phases in Iranian patients
title_sort comparative study on guidelines in determining hbv phases in iranian patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011065/
https://www.ncbi.nlm.nih.gov/pubmed/32099615
work_keys_str_mv AT ashtarisara comparativestudyonguidelinesindetermininghbvphasesiniranianpatients
AT sharifianafsaneh comparativestudyonguidelinesindetermininghbvphasesiniranianpatients
AT hatamibehzad comparativestudyonguidelinesindetermininghbvphasesiniranianpatients
AT mohebbiseyedreza comparativestudyonguidelinesindetermininghbvphasesiniranianpatients
AT nourigholamreza comparativestudyonguidelinesindetermininghbvphasesiniranianpatients
AT bazdarmonireh comparativestudyonguidelinesindetermininghbvphasesiniranianpatients
AT naderinosratollah comparativestudyonguidelinesindetermininghbvphasesiniranianpatients